Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
You may also be interested in...
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
Augmenix is the privately-held developer of SpaceOAR, an injected hydrogel spacer that is indicated for reducing collateral damage from radiation treatment for prostate cancer. It addresses a market worth about $750m, with total sales expected to reach $90m in 2019.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.